In our model, CSF stages could be related to main molecular changes and clinical tipping points in the course of the disease, including abnormal levels of deposited Aβ (CSF stage 2: pT217/T217)19,20,23,25,26,28,29,32 and tau (CSF stage 3: pT205/T205) (refs. 28,29,32), early cognitive impairment (CSF stage 4: MTBR-tau243) (ref. 32) and neurodegeneration (CSF stage 5: np-tau), following the expected pattern. Here, MAPT is linked to Cognitive impairment.